Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Scott R Best"'
Publikováno v:
Oncotarget
Contrary to chemotherapy, novel targeted therapies are associated with diverse immunomodulatory effects. Nedd8 is a small ubiquitin-like modifier that is involved in regulation of protein degradation. Neddylation is a promising target in cancer. Pevo
Autor:
Vi Lam, Nur Bruss, Alexey V. Danilov, Olga V. Danilova, Guang Fan, Tingting Liu, Scott R Best, Adam Kittai
Publikováno v:
Oncotarget
Peripheral T-cell lymphoma (PTCL) is characterized by poor outcomes. We and others have shown that targeting the NEDD8-activating enzyme (NAE) with an investigational inhibitor pevonedistat deregulates cell cycle and mitosis in lymphoma and leukemia.
Autor:
Cody Paiva, Taylor A. Rowland, Bhargava Sreekantham, Claire Godbersen, Scott R. Best, Prabhjot Kaur, Marc M. Loriaux, Stephen E.F. Spurgeon, Olga V. Danilova, Alexey V. Danilov
Publikováno v:
Haematologica, Vol 102, Iss 11 (2017)
Although small molecule inhibitors of B-cell receptor-associated kinases have revolutionized therapy in chronic lymphocytic leukemia (CLL), responses are incomplete. Pro-survival signaling emanating from the microenvironment may foster therapeutic re
Externí odkaz:
https://doaj.org/article/dffc03c8493b480fb0911a096de8be69
Autor:
Adam Kittai, Alexey V. Danilov, Bria Thurlow, Stephen E. Spurgeon, Daniel O. Persky, Shaun M. Goodyear, Byung Park, Taylor Hashiguchi, Vi Lam, Scott R Best, Craig Okada
Publikováno v:
Haematologica
Autor:
Alexey V. Danilov, Adam Kittai, Tingting Liu, Kirsten Orand, Scott R Best, Vi Lam, Stephen E. Spurgeon
Publikováno v:
British journal of clinical pharmacologyREFERENCES. 88(2)
Spleen tyrosine kinase (SYK) is indispensable in B-cell receptor signalling. SYK inhibitor entospletinib demonstrated clinical efficacy in patients with chronic lymphocytic leukaemia (CLL). However, pharmacodynamic effects of SYK inhibition in CLL ce
Autor:
Evan F. Lind, Vi Lam, Nathan D. Pennock, Scott R Best, Adam Kittai, Alexey V. Danilov, Nur Bruss, Allison Berger, Susan E. Murray, Tingting Liu, Olga V. Danilova
Publikováno v:
Leukemia
Novel targeted agents used in therapy of lymphoid malignancies, such as inhibitors of B-cell receptor-associated kinases, are recognized to have complex immune-mediated effects. NEDD8-activating enzyme (NAE) has been identified as a tractable target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcae410fe576a9e2b7a646012b4569dc
https://europepmc.org/articles/PMC8288064/
https://europepmc.org/articles/PMC8288064/
Autor:
Olga V. Danilova, Tanya Siddiqi, Scott R Best, Tingting Liu, Nur Bruss, Alexey V. Danilov, Xiaoguang Wang, Vi Lam, Nathan D. Pennock
Publikováno v:
Blood. 138:3719-3719
Introduction: CLL is characterized by deficient immunity which clinically manifests as increased predisposition towards malignancies and infectious complications. T-cells from patients with CLL exhibit a skewed repertoire with predominance of Tregs a
Autor:
Claire Godbersen, Bhargava Sreekantham, Olga V. Danilova, Scott R Best, Alexey V. Danilov, Cody Paiva, Prabhjot Kaur, Stephen E. Spurgeon, Marc M. Loriaux, Taylor Rowland
Publikováno v:
Haematologica
Although small molecule inhibitors of B-cell receptor-associated kinases have revolutionized therapy in chronic lymphocytic leukemia (CLL), responses are incomplete. Pro-survival signaling emanating from the microenvironment may foster therapeutic re
Publikováno v:
Leukemialymphoma. 60(12)
With the advent of proteasome inhibitors (bortezomib) and pleiotropic pathway modulators which target cereblon E3 ligase (lenalidomide), the ubiquitin-proteasome system has emerged as a tractable target in non-Hodgkin lymphoma and multiple myeloma. H
Autor:
Craig Okada, Alexey V. Danilov, Nur Bruss, Allison Berger, Cody Paiva, Tingting Liu, Adam Kittai, Scott R Best, Taylor Hashiguchi
Publikováno v:
Blood advances. 3(1)
Alterations in the ubiquitin proteasome system (UPS) leave malignant cells in heightened cellular stress, making them susceptible to proteasome inhibition. However, given the limited efficacy of proteasome inhibitors in non-Hodgkin lymphoma (NHL), no